Human cytomegalovirus (HCMV) infects endothelial, epithelial, and glial cells in vivo. These cells can express MHC class II proteins, but are unlikely to play important roles in priming host immunity. Instead, it seems that class II presentation of endogenous HCMV antigens in these cells allows recognition of virus infection. We characterized class II presentation of HCMV glycoprotein B (gB), a membrane protein that accumulates extensively in endosomes during virus assembly. Human CD4+ T cells specific for gB were both highly abundant in blood and cytolytic in vivo. gB-specific CD4+ T cell clones recognized gB that was expressed in glial, endothelial, and epithelial cells, but not exogenous gB that was fed to these cells. Glial cells efficiently presented extremely low levels of endogenous gB—expressed by adenovirus vectors or after HCMV infection—and stimulated CD4+ T cells better than DCs that were incubated with exogenous gB. Presentation of endogenous gB required sorting of gB to endosomal compartments and processing by acidic proteases. Although presentation of cellular proteins that traffic into endosomes is well known, our observations demonstrate for the first time that a viral protein sorted to endosomes is presented exceptionally well, and can promote CD4+ T cell recognition and killing of biologically important host cells.
Skip Nav Destination
Article navigation
17 October 2005
Article|
October 10 2005
Endogenous human cytomegalovirus gB is presented efficiently by MHC class II molecules to CD4 + CTL
Nagendra R. Hegde,
Nagendra R. Hegde
1Department of Molecular Microbiology and Immunology, Veterans Affairs Medical Center
Search for other works by this author on:
Claire Dunn,
Claire Dunn
1Department of Molecular Microbiology and Immunology, Veterans Affairs Medical Center
Search for other works by this author on:
David M. Lewinsohn,
David M. Lewinsohn
2Division of Pulmonary and Critical Care Medicine, Veterans Affairs Medical Center
Search for other works by this author on:
Michael A. Jarvis,
Michael A. Jarvis
3Vaccine and Gene Therapy Institute, Oregon Health & Science University, Portland, OR 97239
Search for other works by this author on:
Jay A. Nelson,
Jay A. Nelson
1Department of Molecular Microbiology and Immunology, Veterans Affairs Medical Center
3Vaccine and Gene Therapy Institute, Oregon Health & Science University, Portland, OR 97239
Search for other works by this author on:
David C. Johnson
David C. Johnson
1Department of Molecular Microbiology and Immunology, Veterans Affairs Medical Center
Search for other works by this author on:
Nagendra R. Hegde
1Department of Molecular Microbiology and Immunology, Veterans Affairs Medical Center
Claire Dunn
1Department of Molecular Microbiology and Immunology, Veterans Affairs Medical Center
David M. Lewinsohn
2Division of Pulmonary and Critical Care Medicine, Veterans Affairs Medical Center
Michael A. Jarvis
3Vaccine and Gene Therapy Institute, Oregon Health & Science University, Portland, OR 97239
Jay A. Nelson
1Department of Molecular Microbiology and Immunology, Veterans Affairs Medical Center
3Vaccine and Gene Therapy Institute, Oregon Health & Science University, Portland, OR 97239
David C. Johnson
1Department of Molecular Microbiology and Immunology, Veterans Affairs Medical Center
CORRESPONDENCE David C. Johnson: [email protected]
Abbreviations used: Ad, adenovirus; BAC, bacterial artificial chromosome; CT, cytoplasmic tail; gB, glycoprotein B; gH, glycoprotein H; HCMV, human CMV; LCL, lymphoblastoid cell line; TAP, transporter associated with antigen presentation; TB, tuberculosis; TGN, trans-Golgi network; US, unique short.
N.R. Hegde and C. Dunn contributed equally to this work.
Received:
January 19 2005
Accepted:
September 01 2005
Online ISSN: 1540-9538
Print ISSN: 0022-1007
The Rockefeller University Press
2005
J Exp Med (2005) 202 (8): 1109–1119.
Article history
Received:
January 19 2005
Accepted:
September 01 2005
Citation
Nagendra R. Hegde, Claire Dunn, David M. Lewinsohn, Michael A. Jarvis, Jay A. Nelson, David C. Johnson; Endogenous human cytomegalovirus gB is presented efficiently by MHC class II molecules to CD4+ CTL . J Exp Med 17 October 2005; 202 (8): 1109–1119. doi: https://doi.org/10.1084/jem.20050162
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement